雪榕生物:2024年报净利润-6.17亿 同比下降228.19%

Financial Performance - The company reported a basic earnings per share of -1.2400 yuan for 2024, a decrease of 226.32% compared to -0.3800 yuan in 2023 [1] - The net profit for 2024 was -6.17 billion yuan, representing a decline of 228.19% from -1.88 billion yuan in 2023 [1] - The return on equity (ROE) for 2024 was -49.50%, a significant drop from -11.41% in 2023, indicating worsening profitability [1] - Total revenue decreased to 21.62 billion yuan in 2024, down 15.71% from 25.65 billion yuan in 2023 [1] - The net asset per share fell to 1.74 yuan, a decrease of 41.41% from 2.97 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 62.53 million shares, accounting for 14.95% of the circulating shares, a decrease of 4.93 million shares from the previous period [2] - Major shareholders include Yang Yongping with 26.90 million shares (6.44%), and Zhejiang Yinwan Private Fund Management Co., Ltd. with 18.73 million shares (4.48%), both unchanged [3] - New entrants among the top shareholders include J.P. Morgan Securities PLC with 2.01 million shares (0.48%) and Beijing Xinhong Tianhe Asset Management Center with 1.92 million shares (0.46%) [3] - Notable exits from the top ten shareholders include Gao Anqi and MERRILL LYNCH INTERNATIONAL, indicating a shift in shareholder composition [3][4] Dividend Policy - The company has announced no distribution or capital increase for the current period [5]